Results 81 to 90 of about 12,566 (189)

Neurofibromatosis Type 1 and Diabetes Mellitus: An Unusual Association

Case Reports in Endocrinology, 2013
Neurofibromatosis type 1 is a multisystemic disease. It may manifest as abnormalities of the nervous tissue, bones, soft tissue, or skin. Autoimmune disease associated with NF1 can be seen. Diabetes mellitus is rarely seen in association with NF1.
Bayram Ozhan, Ali Aykan Ozguven, Betül Ersoy   +2 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Inhibition of Anaplastic Lymphoma Kinase (Alk) as Therapeutic Target to Improve Brain Function in Neurofibromatosis Type 1 (Nf1). [PDF]

Cancers (Basel), 2023
Weiss JB, Raber J.
europepmc   +1 more source

Neurofibromatosis type 1: Clinical characteristics and mutation spectrum in a North Indian cohort

Heliyon
Background: Neurofibromatosis type 1 (NF1) is a unique, highly penetrant neuro-cutaneous disorder with a wide range of manifestations. Though the clinical diagnosis of NF1 is straight forward, there can be other disorders which mimic NF1, especially its ...
Priyanka Srivastava, Shifali Gupta, Chitra Bamba, Roshan Daniel, Parminder Kaur, Anupriya Kaur, Inusha Panigrahi, Kausik Mandal   +7 more
doaj   +1 more source

Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care. [PDF]

Pediatric Health Med Ther, 2023
Radtke HB, Berger A, Skelton T, Goetsch Weisman A.   +3 more
europepmc   +1 more source

Are neurofibromatosis type 1 (NF1) patients at increased risk of meningioma and in particular malignant meningioma? [PDF]

AME Case Rep, 2022
Evans DGR, Lunt L.
europepmc   +1 more source

Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. [PDF]

Cancers (Basel), 2023
Pillay-Smiley N, Leach J, Lane A, Hummel T, Fangusaro J, de Blank P.   +5 more
europepmc   +1 more source

Neuropsychiatric Manifestations, Reduced Self-Esteem and Poor Quality of Life in Children and Adolescents with Neurofibromatosis Type 1 (NF1): The Impact of Symptom Visibility and Bullying Behavior. [PDF]

Children (Basel), 2023
Cavallo ND, Maggi G, Ferraiuolo F, Sorrentino A, Perrotta S, Carotenuto M, Santangelo G, Santoro C.   +7 more
europepmc   +1 more source

Laryngeal neurofibroma: case report and review of the literature

Frontiers in Oncology
BackgroundLaryngeal neurofibromatosis (LNF) represents an exceedingly rare manifestation of neurofibromatosis type 1 (NF1), a genetic disorder affecting neural tissue development with an incidence of approximately 1:3000 live births.
Yaya Gao, Wei Mo, Hanwen Zhu, Yunhan Zhang, Hui Yang   +4 more
doaj   +1 more source

Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. [PDF]

NPJ Genom Med, 2021
Koster R, Brandão RD, Tserpelis D, van Roozendaal CEP, van Oosterhoud CN, Claes KBM, Paulussen ADC, Sinnema M, Vreeburg M, van der Schoot V, Stumpel CTRM, Broen MPG, Spruijt L, Jongmans MCJ, Lesnik Oberstein SAJ, Plomp AS, Misra-Isrie M, Duijkers FA, Louwers MJ, Szklarczyk R, Derks KWJ, Brunner HG, van den Wijngaard A, van Geel M, Blok MJ.   +24 more
europepmc   +1 more source